Reinforced vascular prostheses
View Patent ↗Vascular grafts for treating, reconstructing and replacing damaged or diseased cardiovascular vessels that are formed from decellularized extracellular matrix (ECM). The vascular grafts include outer or outer and inner coatings that provide structural reinforcement.
1. A vascular graft for treating damaged or diseased tissue in cardiovascular vessels, comprising:
a biodegradable and remodelable tubular member comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source and a growth factor selected from the group consisting of a transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), fibroblast growth factor-2 (FGF-2), and vascular epithelial growth factor (VEGF), said tubular member comprising an outer surface and a lumen that extends therethrough, said lumen defining a tubular member inner surface;
said tubular member further comprising at least one biodegradable coating disposed on said tubular member outer surface, said biodegradable coating comprising an ECM-mimicking biomaterial composition comprising poly(glycerol sebacate),
said tubular member further comprises a first reinforcing structure disposed proximate the outer surface, said first reinforcing structure comprises poly (glycerol sebacate),
said tubular member being configured to induce modulated healing when disposed proximate damaged cardiovascular tissue, said modulated healing comprising modulation of inflammation of said damaged tissue, and induced host tissue proliferation, bioremodeling of said damaged tissue, and regeneration of new cardiovascular tissue and tissue structures with site specific structural and functional properties.
2. The vascular graft of claim 1 , wherein said mammalian tissue source is selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS), and mesothelial tissue.
3. The vascular graft of claim 2 , wherein said ECM composition further comprises at least one supplemental biologically active agent.
4. The vascular graft of claim 3 , wherein said supplemental biologically active agent comprises a cell selected from the group consisting of a human embryonic stem cell, fetal cardiomyocyte, myofibroblast, and mesenchymal stem cell.
5. The vascular graft of claim 1 , wherein said acellular ECM material comprises adolescent acellular ECM.
6. The vascular graft of claim 1 , wherein said ECM composition further comprises a pharmacological agent.
7. The vascular graft of claim 6 , wherein said pharmacological agent comprises an agent selected from the group consisting of an antibiotic, anti-viral agent, analgesic, anti-inflammatory, anti-neoplastic, anti-spasmodic, anticoagulant and antithrombotic agent.
8. The vascular graft of claim 6 , wherein said pharmacological agent comprises a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
9. The vascular graft of claim 8 , wherein said statin is encapsulated in a second osmotic fluctuation inducing composition.
10. The vascular graft of claim 9 , wherein said tubular member comprises a multi-stage delivery vehicle.
11. The vascular graft of claim 1 , wherein said first reinforcing structure comprises a woven structure.
12. The vascular graft of claim 1 , wherein said first reinforcing structure comprises a second polymeric composition coating comprising a polymeric material selected from the group consisting of poly(ε-caprolactone-co-glycolide)(PCL), polyhydroxy-alkonate (PHA), polylactide (PLLA) and polyglycolide (PLGA) and its copolymers, and polyanhydride.
13. The vascular graft of claim 1 , wherein said tubular member further comprises a second reinforcing structure.
14. The vascular graft of claim 13 , wherein said second reinforcing structure comprises a mesh structure.
15. The vascular graft of claim 14 , wherein said mesh reinforcing structure comprises Nitinol®.
16. The vascular graft of claim 1 , wherein said growth factor is encapsulated in a first osmotic fluctuation inducing composition.
17. The vascular graft of claim 1 , wherein said acellular ECM comprises acellular ECM selected from the group consisting of subcutaneous extracellular matrix, large intestine extracellular matrix, placental extracellular matrix, omentum extracellular matrix, heart extracellular matrix and lung extracellular matrix.